2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.094 Arvind Kumar NACLC2023 Abstract

PP01.094 Arvind Kumar NACLC2023 Abstract

Pdf Summary

A study was conducted to evaluate the impact of timing of systemic therapy on overall survival in patients with non-small-cell lung cancer (NSCLC) and brain oligometastases. The study included patients with stage IV NSCLC who had limited metastases isolated to the brain and received systemic therapy and radical treatment to the lung and brain.<br /><br />The study analyzed data from the National Cancer Database from 2010 to 2019. Patients were divided into three groups based on the timing of systemic therapy: pre-radical treatment, concurrent with radical treatment, and post-radical treatment. The survival of patients in each group was evaluated using Kaplan-Meier analysis after propensity score matching.<br /><br />Out of 668 eligible patients, 3.1% received pre-radical treatment systemic therapy, 64.5% received concurrent therapy, and 32.3% received post-radical treatment therapy. It was found that post-radical treatment systemic therapy was more common among patients who underwent lung resection, while concurrent therapy was more common among patients who underwent lung radiation.<br /><br />A propensity score-matched analysis of 84 patients each who received concurrent and post-radical treatment systemic therapy demonstrated similar 5-year overall survival rates. This was consistent both in the entire cohort and in a landmark analysis of patients who survived at least 6 months after diagnosis. The results showed that the timing of systemic therapy did not significantly impact overall survival.<br /><br />In conclusion, this study suggests that the timing of systemic therapy does not have a significant influence on the overall survival of patients with NSCLC and brain oligometastases. The most common practice was to administer systemic therapy concurrently with radical treatments. These findings provide valuable information for treatment decision-making in patients with NSCLC and brain-only metastases.

Keywords

systemic therapy

timing

overall survival

non-small-cell lung cancer

NSCLC

brain oligometastases

radical treatment

lung resection

lung radiation

propensity score matching